Sagimet Biosciences Announces Appointment of Anne Phillips and Jennifer Jarrett to its Board of DirectorsSAN MATEO, Calif., Aug. 01, 2024 (GLOBE NEWSWIRE) -- Sagimet Biosciences Inc. (Sagimet, Nasdaq: SGMT), a clinical-stage biopharmaceutical company developing novel fatty acid synthase (FASN) inhibitors designed to target dysfunctional metabolic and fibrotic pathways, today announced the appointments of two biotechnology industry leaders, Anne Phillips and Jennifer Jarrett, to the board of directors of the Company, effective August 1, 2024.
Global Alzheimer’s Disease Diagnostics & Therapeutics Market Expected to Reach $9.6 Billion by 2027Palm Beach, FL – May 9, 2023 – FinancialNewsMedia.com News Commentary – Alzheimer’s disease (AD) is a progressive and neurodegenerative disorder that attacks the brain’s nerve cells or neurons, which results in loss of memory, thinking and language skills, and behavioral changes. There is a rapid growth in the number of people living with Alzheimer’s […]
Trevena Inc. (NASDAQ: TRVN) Near the Top of Equities by Percentage Gain on 5/8Trevena, Inc. (
NASDAQ: TRVN) is one of today’s top gainers. The company’s shares are currently up 372.94% on the day to $3.05.
Trevena (NASDAQ: TRVN) Partner Receives Approval for OLINVYK in ChinaTrevena, Inc. (
NASDAQ: TRVN) is engaged as a biopharmaceutical company, which is focused on the research, development and commercialization of